drugset / Trial / NCT07059949
Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer
Phase 2
Not yet recruiting
80 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of short-course radiotherapy followed by CAPOX and carrilizumab and bevacizumab or cetuximab in the initial treatment of unresectable metastatic rectal cancer
Timeline
- Start
- 2025-06-30
- Primary completion
- 2027-01-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Background | Camrelizumab | Monoclonal antibody | — | — |